Early detection
Diadem
Investment: Fund IBlood-based diagnostics for Alzheimer’s disease and other neurodegenerative conditions.
Visit Website
Blood-Based Insight into Neurodegenerative Disease
Diadem is developing blood-based technologies for Alzheimer’s disease and other neurodegenerative conditions. Its work focuses on biomarkers associated with cognitive decline and the potential for earlier insight.
Advancing Earlier Detection
Diadem aligns with Seed’s focus on early detection. Seed’s published investment announcement describes support for the company’s U.S. commercialization.
Company profile by Seed Healthcare. Visit Diadem’s website for current company information.